Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006260 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy in Treating Patients With Metastatic Breast Cancer
A Phase 2 study, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT00006260 is a Phase 2 study that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 36 participants.
The verdict
NCT00006260, a Phase 2 study, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Drugs such as mesna may be effective in preventing some of the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy consisting of etoposide and ifosfamide given with mesna, and cisplatin in treating patients who have metastatic breast cancer.
Interventions
- DRUG Mesna
- DRUG cisplatin
- DRUG etoposide
- DRUG ifosfamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 1997-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006260
The ClinicalTrials.gov registry entry for NCT00006260 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Mesna is the first listed.
NCT00006260 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00006260 about?
NCT00006260 is a clinical study titled "Combination Chemotherapy in Treating Patients With Metastatic Breast Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Drugs such as mesna may be effective in preventing some of the side effects of chemotherapy. PURPOSE: Phase II trial to stu...
What is the current status of trial NCT00006260?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 1997-05.
What interventions are being tested in trial NCT00006260?
The interventions under investigation include: Mesna (DRUG), cisplatin (DRUG), etoposide (DRUG), ifosfamide (DRUG).
Who is sponsoring clinical trial NCT00006260?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.